带状疱疹活疫苗与Medicare受益人卒中风险关联的队列研究
中位随访5.1年显示,接种者全卒中、急性缺血性卒中和出血性卒中调整风险比分别为0.84、0.83和0.88,均显著低于未接种者。结论提示接种ZVL与较低卒中发生率相关。
要点
- 急性缺血性卒中和出血性卒中风险亦降低(aHR 0.83和0.88)。
- 年轻、未用降压或他汀药及合并症较少者关联更强。
核心结论
- 在Medicare按服务付费受益人中,接种ZVL与较低卒中发生率相关。
- 该发现可能鼓励人们接种带状疱疹疫苗以降低带状疱疹及带状疱疹相关卒中风险。
研究设计与样本
- 采用Cox比例风险模型分析ZVL与致死性或非致死性新发卒中复合结局的关联。
主要发现
- 中位随访5.1年(四分位距3.9–6.7),接种组在8 755 331人年中记录64 635例卒中事件,包括43 954例急性缺血性卒中和6 727例出血性卒中。
- 未接种组在8 517 322人年中记录73 023例卒中、50 476例急性缺血性卒中和7 276例出血性卒中。
- 接种组与未接种组全卒中发生率分别为7.38 vs 8.57/1000人年,急性缺血性卒中5.00 vs 5.90,出血性卒中0.76 vs 0.84(所有差异P<0.001)。
- 接种组与未接种组全卒中、急性缺血性卒中和出血性卒中的调整风险比分别为0.84(95%CI 0.83–0.85)、0.83(0.82–0.84)和0.88(0.85–0.91)。
- ZVL与卒中风险的关联在较年轻、未服用降压药或他汀类药物及合并症较少的受益人中更强(交互作用P<0.05),但在性别、低收入状态和种族组间基本一致。
临床怎么用
- 对于≥66岁无卒中史的老年人,接种ZVL可能与较低卒中风险相关,可结合带状疱疹预防策略综合评估。
- 该关联在较年轻、未用降压或他汀药物及合并症较少者中更明显,可作为个体化接种沟通的参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Herpes zoster (HZ) is associated with increased risk of stroke, and zoster vaccine live (ZVL, Zostavax) reduces the risk of HZ. No study has examined the association between ZVL (Zostavax) and risk of stroke. Present study examined association between receipt of ZVL (Zostavax) and risk of stroke among older US population. METHODS: Our study included 1 603 406 US Medicare fee-for-service beneficiaries aged ≥66 years without a history of stroke and who received ZVL (Zostavax) during 2008 to 2014, and 1 603 406 propensity score-matched unvaccinated beneficiaries followed through to December 31, 2017. We used Cox proportional hazard models to examine association between ZVL (Zostavax) and composite fatal or nonfatal incident stroke outcomes. RESULTS: During a median of 5.1 years follow-up (interquartile range, 3.9–6.7), we documented 64 635 stroke events, including 43 954 acute ischemic strokes and 6727 hemorrhagic strokes, among vaccinated beneficiaries during 8 755 331 person-years. The corresponding numbers among unvaccinated beneficiaries were 73 023, 50 476, and 7276, respectively, during 8 517 322 person-years. Incidence comparing vaccinated to unvaccinated beneficiaries were 7.38 versus 8.57 per 1000 person-years for all stroke, 5.00 versus 5.90 for acute ischemic stroke, and 0.76 versus 0.84 for hemorrhagic stroke (P<0.001 for all difference). Adjusted hazard ratios comparing vaccinated to unvaccinated beneficiaries were 0.84 (95% CI, 0.83–0.85), 0.83 (0.82–0.84), and 0.88 (0.85–0.91) for all stroke, acute ischemic stroke, and hemorrhagic stroke, respectively. The association between ZVL (Zostavax) and risk of stroke appeared to be stronger among younger beneficiaries, beneficiaries who did not take antihypertensive or statin medications and who had fewer comorbid conditions (P<0.05 for interaction) but largely consistent across sex, low-income status, and racial groups. CONCLUSIONS: Among Medicare fee-for-service beneficiaries, receipt of ZVL (Zostavax) was associated with lower incidence of stroke. Our findings may encourage people to get vaccinated against HZ to reduce HZ and HZ-associated stroke risk.
引用
- Yang Q, Chang A, Tong X, et al. Herpes Zoster Vaccine Live and Risk of Stroke Among Medicare Beneficiaries: A Population-Based Cohort Study. Stroke. 2021. PMID: 33874749. doi:10.1161/STROKEAHA.120.032788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。